Exploring the Influence of Concurrent Nutritional Therapy on Children with Spinal Muscular Atrophy Receiving Nusinersen Treatment

被引:0
|
作者
Pinar, Eymen [1 ]
Ayvaz, Bilal Berke [1 ]
Akkus, Erkan [2 ]
Ulkersoy, Ipek [2 ]
Dilek, Tugce Damla [3 ]
Zindar, Yilmaz [3 ]
Ulug, Fitnat [3 ]
Guzeler, Aysel [3 ]
Kilic, Huseyin [3 ]
Guler, Serhat [3 ]
Beser, Omer Faruk [2 ]
Saltik, Sema [3 ]
Cullu Cokugras, Fugen [2 ]
机构
[1] Istanbul Univ, Cerrahpasa Med Fac, Dept Pediat, Pediat, TR-34000 Istanbul, Turkiye
[2] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Pediat, Div Pediat Gastroenterel Hepatol & Nutr, TR-23119 Istanbul, Turkiye
[3] Istanbul Univ Cerrahpasa, Cerrahpasa Med Fac, Dept Pediat, Div Pediat Neurol, TR-34000 Istanbul, Turkiye
来源
CHILDREN-BASEL | 2024年 / 11卷 / 08期
关键词
motor functions; malnutrition; screening tools; nutritional intervention; PYMS; STAMP; 3 SCREENING TOOLS; SHAM CONTROL; MALNUTRITION; MANAGEMENT; RISK; DIAGNOSIS;
D O I
10.3390/children11080886
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background This study examines spinal muscular atrophy (SMA), a neuromuscular disease associated with malnutrition. Our goals are to assess how effectively screening tools can detect malnutrition and evaluate the impact of nutritional interventions on neurological outcomes, particularly motor functions. Methods Thirty-seven genetically diagnosed SMA patients (types 1, 2, and 3) under nusinersen therapy were included in the study. The nutritional status of these patients was assessed by using anthropometric measurements, including height for age (HFA), weight for height (WFH), and body mass index (BMI) before and after the study. Additionally, the risk of malnutrition was determined using screening tools, namely the Pediatric Yorkhill Malnutrition Score (PYMS) and the Screening Tool for the Assessment of Malnutrition in Pediatrics (STAMP). Nutritional counseling followed the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) guidelines and considered the patients' dietary history, including content and administration method. Motor functions were assessed by validated tests: the Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) and the Hammersmith Functional Motor Scale-Expanded (HFMSE). Result The study showed an improvement in HFA, by a change from -0.95 to -0.65 (p = 0.015). Conversely, BMI scores decreased from 0.08 to -0.54 (p = 0.015), while WFH and MUAC showed no significant alterations (p = 0.135, p = 0.307). Following nutritional interventions, HFMSE demonstrated a median increase from 29.5 to 30.5 (p = 0.023). Patients identified as being at high risk for malnutrition based on PYMS and STAMP belonged to the moderate-to-severe malnutrition group (BMI Z-score <= -2, p = 0.001). Conclusions Use of screening tools in SMA patients is highly beneficial for the early detection of malnutrition. Future research should highlight the importance of combining nutritional management with nusinersen therapy to potentially alter the disease trajectory, especially in motor and neurological functions.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Analysis of the efficacy and adverse effects of nusinersen in the treatment of children with spinal muscular atrophy in China
    Li, Dan
    Yang, Jie
    Wang, Xueying
    Yang, Lin
    Luo, Rong
    Huang, Shaoping
    BRAIN AND BEHAVIOR, 2024, 14 (07):
  • [32] CSF Biomarkers of Disease Severity and Response to Nusinersen Treatment in Children with Spinal Muscular Atrophy
    Fadda, Giulia
    Kichula, Elizabeth
    Bacchus, Micky
    Brown, Robert
    Zhao, Ling
    Waldman, Amy
    Augelli, Brian
    Banwell, Brenda
    Bar-Or, Amit
    NEUROLOGY, 2020, 94 (15)
  • [33] Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
    Kizina, K.
    Stolte, B.
    Totzeck, A.
    Bolz, S.
    Schlag, M.
    Ose, C.
    von Velsen, O.
    Kleinschnitz, C.
    Hagenacker, Tim
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [34] Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy
    Osmanovic, Alma
    Ranxha, Gresa
    Kumpe, Mareike
    Wurster, Claudia D.
    Stolte, Benjamin
    Cordts, Isabell
    Guenther, Rene
    Freigang, Maren
    Mueschen, Lars H.
    Binz, Camilla
    Hermann, Andreas
    Deschauer, Marcus
    Lingor, Paul
    Ludolph, Albert C.
    Hagenacker, Tim
    Schreiber-Katz, Olivia
    Petri, Susanne
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [35] Nusinersen treatment in spinal muscular atrophy: the experience of Bambino Gesu Children's Hospital
    D'Amico, A.
    Catteruccia, M.
    Cherchi, C.
    Chiarini, M.
    Colia, G.
    Bonetti, A.
    Carlesi, A.
    Rollo, M.
    Longo, A.
    Nicita, F.
    Corsetti, T.
    Bianchi, R.
    Cutrera, R.
    Bertini, E.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S189 - S190
  • [36] Experience of nusinersen treatment to adult patients with spinal muscular atrophy
    Saito, T.
    Matsuoka, Y.
    Odani, H.
    Matsumura, T.
    Nishio, H.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S137 - S138
  • [37] Spinal muscular atrophy 5Q-Treatment with nusinersen
    Silvinato, Antonio
    Bernardo, Wanderley M.
    REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2018, 64 (06): : 484 - 491
  • [38] Fatigue in adults with spinal muscular atrophy under treatment with nusinersen
    K. Kizina
    B. Stolte
    A. Totzeck
    S. Bolz
    M. Schlag
    C. Ose
    O. von Velsen
    C. Kleinschnitz
    Tim Hagenacker
    Scientific Reports, 10
  • [39] Pre-Nusinersen Hospitalization Costs of Children With Spinal Muscular Atrophy
    Lee, Michael, Jr.
    Franca, Urbano L.
    Graham, Robert J.
    McManus, Michael L.
    PEDIATRIC NEUROLOGY, 2019, 92 : 3 - 5
  • [40] The Effect of Nusinersen Therapy on Laboratory Parameters of Patients with Spinal Muscular Atrophy
    Uzan, Gamze Sarikaya
    Paketci, Cem
    Gunay, Cagatay
    Edem, Pinar
    Ozsoy, Ozlem
    Kurul, Semra Hiz
    Yis, Uluc
    NEUROPEDIATRICS, 2022, 53 (05) : 321 - 329